After safety concerns, Novartis launches external review of Beovu

26 February 2020
eye_stock_large-1-

With stocks reeling over safety concerns for blindness medicine Beovu (brolucizumab), Swiss pharma giant Novartis (NOV: NX) has begun an external review into the product.

Shares have fallen an astonishing 9% since the American Society of Retinal Specialists (ASRS) issued a communication to its members that could alter the risk/benefit profile for the macular degeneration drug.

Intended as a replacement for aging blockbuster Lucentis (ranibizumab), Novartis won approval from the US Food and Drug Administration in October 2019 and in Europe in February 2020.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology